- Home
- FURY vs INZY Comparison
FURY vs INZY Comparison
Compare FURY & INZY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FURY
- INZY
- Stock Information
- Founded
- FURY 2008
- INZY 2015
- Country
- FURY Canada
- INZY United States
- Employees
- FURY N/A
- INZY N/A
- Industry
- FURY Precious Metals
- INZY Biotechnology: Pharmaceutical Preparations
- Sector
- FURY Basic Materials
- INZY Health Care
- Exchange
- FURY Nasdaq
- INZY Nasdaq
- Market Cap
- FURY 60.5M
- INZY 64.9M
- IPO Year
- FURY N/A
- INZY 2020
- Fundamental
- Price
- FURY $0.39
- INZY $0.92
- Analyst Decision
- FURY Strong Buy
- INZY Strong Buy
- Analyst Count
- FURY 1
- INZY 9
- Target Price
- FURY $1.10
- INZY $17.22
- AVG Volume (30 Days)
- FURY 154.5K
- INZY 453.8K
- Earning Date
- FURY 05-13-2025
- INZY 05-06-2025
- Dividend Yield
- FURY N/A
- INZY N/A
- EPS Growth
- FURY N/A
- INZY N/A
- EPS
- FURY N/A
- INZY N/A
- Revenue
- FURY N/A
- INZY N/A
- Revenue This Year
- FURY N/A
- INZY N/A
- Revenue Next Year
- FURY N/A
- INZY N/A
- P/E Ratio
- FURY N/A
- INZY N/A
- Revenue Growth
- FURY N/A
- INZY N/A
- 52 Week Low
- FURY $0.35
- INZY $0.72
- 52 Week High
- FURY $0.57
- INZY $6.24
- Technical
- Relative Strength Index (RSI)
- FURY 53.97
- INZY 44.29
- Support Level
- FURY $0.35
- INZY $0.83
- Resistance Level
- FURY $0.41
- INZY $1.08
- Average True Range (ATR)
- FURY 0.02
- INZY 0.11
- MACD
- FURY 0.00
- INZY 0.02
- Stochastic Oscillator
- FURY 73.77
- INZY 55.43
About FURY Fury Gold Mines Limited
Fury Gold Mines Ltd is a Canadian-focused exploration and development company strategically positioned in three prolific mining regions: James Bay, Quebec; the Golden Triangle, British Columbia; and the Kitikmeot Region Nunavut. Its projects include Eau Claire, Homestake Ridge, Committee Bay, Eleonore South JV, and Gibson MacQuoid.
About INZY Inozyme Pharma Inc.
Inozyme Pharma Inc is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of diseases impacting bone health and blood vessel function. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies. Its product candidate, INZ-701, is a soluble, recombinant, genetically engineered fusion protein that is designed to correct a defect in a pathway involving ENPP1 and ABCC6 deficiencies.